Provectus Biopharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $0.07
50-Day Range
MA: $0.07
52-Week Range
Now: $0.07
Volume141,903 shs
Average Volume413,262 shs
Market Capitalization$26.72 million
P/E RatioN/A
Dividend YieldN/A
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal disodium (cGMP RBD) for the treatment of adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; and multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Provectus Biopharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:PVCT
Previous SymbolNYSEMKT:PVCT
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share


Net Income$-6,920,000.00


Market Cap$26.72 million
Next Earnings Date5/12/2021 (Estimated)
OptionableNot Optionable


News for Provectus Biopharmaceuticals Inc
December 24, 2020 |  markets.businessinsider.com
See More Headlines


Overall MarketRank

0.60 out of 5 stars

Medical Sector

1380th out of 2,025 stocks

Pharmaceutical Preparations Industry

597th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions

What stocks does MarketBeat like better than Provectus Biopharmaceuticals?

Wall Street analysts have given Provectus Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Provectus Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Provectus Biopharmaceuticals' next earnings date?

Provectus Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for Provectus Biopharmaceuticals

How has Provectus Biopharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Provectus Biopharmaceuticals' stock was trading at $0.0445 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PVCT stock has increased by 48.8% and is now trading at $0.0662.
View which stocks have been most impacted by COVID-19

Who are Provectus Biopharmaceuticals' key executives?

Provectus Biopharmaceuticals' management team includes the following people:
  • Dr. Eric A. Wachter, Co-Founder & CTO (Age 58, Pay $478.05k)
  • Ms. Heather Raines CPA, Chief Financial Officer (Age 54, Pay $130.81k)
  • Mr. Bruce Horowitz, COO & Director (Age 65, Pay $352.2k)

Who are some of Provectus Biopharmaceuticals' key competitors?

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Nasdaq Biotechnology ETF (IBB) and MaxLinear (MXL).

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provectus Biopharmaceuticals' stock price today?

One share of PVCT stock can currently be purchased for approximately $0.07.

How much money does Provectus Biopharmaceuticals make?

Provectus Biopharmaceuticals has a market capitalization of $26.72 million.

How many employees does Provectus Biopharmaceuticals have?

Provectus Biopharmaceuticals employs 2 workers across the globe.

What is Provectus Biopharmaceuticals' official website?

The official website for Provectus Biopharmaceuticals is www.provectusbio.com.

Where are Provectus Biopharmaceuticals' headquarters?

Provectus Biopharmaceuticals is headquartered at 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 866-594-5999 or via email at [email protected]

This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.